11th May 2018 08:45
LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Friday that initial review of the Phase III trial for Traumakine drug used for the treatment of lung inflammation did not produce the expected results seen in previous trials for the drug.
"Early analysis of certain biomarker indicators suggest that the treatment did not produce the expected interferon-beta bioactivity in the treatment group that was previously seen in Faron's Phase I/II trial for Traumakine," Faron said, adding that it was too early to fully understand the results.
The clinical stage biopharmaceutical company has been conducting trials for Traumakine to treat acute respiratory distress syndrome. It intends to undertake further detailed analysis of the trial data and testing of product batches.
Separately, much larger peer AstraZeneca PLC revealed Friday that its Galathea Phase III trial for Fasenra drug did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with chronic obstructive pulmonary disease, which causes obstruction of airflow in lungs.
AstraZeneca intends to await results of a separate Fasenra trial called Terranova to determine next steps for Fasenra in COPD. The Galathea trial results do not impact the approved indication of Fasenra in severe eosinophilic asthma.
Shares in Faron were trading up 2.3% lower at 156.00 pence each early Friday. AstraZeneca shares were down 0.8% at 5,211.00p.
Related Shares:
AstrazenecaFaron Pharmaceuticals